Jana Reynolds, MD
Medical Oncology · Dallas, TXNPI 1164656435
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,039 of the $2,485 with a category attached, or 82.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 8.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $957 and has fallen 75.1% since, to $238 in 2025. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 92 payments — averaging $27.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$208
- Sanofi-aventis U.S. LLC$182
- Astellas Pharma US Inc$181
- Pharmacyclics LLC, An Abbvie Company$144
- Takeda Pharmaceuticals U.S.A., Inc.$135
- GSK$127
- plus $2K from 28 others
Across 221 payments — averaging $2257.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$172K
- Pfizer$94K
- Sanofi US Services Inc.$57K
- ADC Therapeutics America, Inc.$51K
- Janssen Research & Development, LLC$32K
- Amgen$31K
- plus $62K from 4 others
What the payments were for
- Food & beverage$2,03982%
- Education$44518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- clonoSEQ$125
How this compares
$2,485 in reported general payments places this provider in the 40th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 83 | $1,023,717 |
| PomalystPomalidomide | 22 | $458,955 |
| RezurockBelumosudil Mesylate | 12 | $429,851 |
| RevlimidLenalidomide | 11 | $198,001 |
| DopteletAvatrombopag Maleate | 11 | $120,393 |
| ValacyclovirValacyclovir Hcl | 70 | $2,621 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $1,298 |
| Tacrolimus | 12 | $904 |
| Acyclovir | 82 | $643 |
| Gabapentin | 39 | $474 |
| Dexamethasone | 23 | $418 |
| Duloxetine Hcl | 19 | $215 |
| Ondansetron OdtOndansetron | 15 | $154 |
| Pantoprazole Sodium | 29 | $149 |
| Escitalopram Oxalate | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $120 | $1,023,71783 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $14 | $458,95522 claims |
| Sanofi-aventis U.S. LLCRezurock | $182 | $429,85112 claims |
| Bristol Myers SquibbRevlimid | $55 | $198,00111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.